<DOC>
	<DOCNO>NCT02282059</DOCNO>
	<brief_summary>This study multi-center , prospective , non-interventional ( NI ) study evaluate safety efficacy sunitinib Chinese patient progressive , unresectable , advanced metastatic well-differentiated , pancreatic neuroendocrine tumor ( pNET ) . 100 adult progressive advance metastatic well-differentiated unresectable pNET recruit China hospital . Each subject follow overall survival ( OS ) time date withdrawal subject remain alive study completion OS time censor last date know alive . Eligible subject enrol receive least one dose sunitinib orally 37.5 mg day continuous daily dose regimen ( CDD ) dosage modification base daily clinic practice . Subjects treat disease progress , unacceptable toxicity , withdrawal study request , final analysis study perform . The NI study capture observation use evaluate safety profile sunitinib , include : subject demographic , medical history medication . Safety assessment , treatment data laboratory examination result , do accord routine clinical practice , collect visit .</brief_summary>
	<brief_title>The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors</brief_title>
	<detailed_description>The sunitinib non-interventional ( NI ) study real world observational study represent usual customary treatment patient propose collect data systematically assess safety efficacy Chinese patient progressive , unresectable , advanced metastatic well-differentiated , pancreatic neuroendocrine tumors.It design conduct meet CFDA post-marketing commitment . non-probability sample</detailed_description>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Evidence personally sign date informed consent document indicate subject ( legally acceptable representative ) inform pertinent aspect study . Subjects willing follow visit within current clinical practice . Histologically cytologically proven diagnosis welldifferentiated pancreatic neuroendocrine tumor ( accord WHO 2000 classification ) Unresectable ( assessed investigator ) metastatic disease document scan A minimum age 18 year Patients poorlydifferentiated pancreatic neuroendocrine tumor ( accord WHO 2000 classification ) Patients receive least one dosage sunitinib treatment prior sign inform consent form exclude participate study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>